$11.58 Million in Sales Expected for Intellia Therapeutics Inc (NTLA) This Quarter

Analysts forecast that Intellia Therapeutics Inc (NASDAQ:NTLA) will report sales of $11.58 million for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Intellia Therapeutics’ earnings, with estimates ranging from $7.00 million to $25.40 million. Intellia Therapeutics posted sales of $7.32 million during the same quarter last year, which would indicate a positive year over year growth rate of 58.2%. The firm is scheduled to report its next earnings report on Tuesday, October 30th.

On average, analysts expect that Intellia Therapeutics will report full year sales of $38.70 million for the current fiscal year, with estimates ranging from $29.15 million to $58.40 million. For the next fiscal year, analysts expect that the firm will report sales of $38.91 million, with estimates ranging from $20.00 million to $58.30 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Wednesday, August 1st. The company reported ($0.52) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.03. Intellia Therapeutics had a negative net margin of 284.56% and a negative return on equity of 31.54%. The firm had revenue of $7.68 million for the quarter, compared to analyst estimates of $6.39 million. During the same period in the prior year, the firm earned ($0.45) earnings per share. The business’s quarterly revenue was up 30.2% compared to the same quarter last year.

NTLA has been the topic of a number of recent research reports. Raymond James initiated coverage on shares of Intellia Therapeutics in a research note on Thursday, September 20th. They set a “market perform” rating on the stock. BidaskClub upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, September 15th. ValuEngine lowered shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, September 22nd. Zacks Investment Research lowered shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 7th. Finally, Chardan Capital restated a “buy” rating and set a $57.50 target price on shares of Intellia Therapeutics in a research note on Friday, August 24th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $39.50.

Shares of NTLA stock traded down $1.00 during trading hours on Friday, reaching $22.19. 363,600 shares of the stock were exchanged, compared to its average volume of 895,199. Intellia Therapeutics has a 12-month low of $16.33 and a 12-month high of $35.99. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -11.80 and a beta of 3.13.

A number of institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC increased its stake in Intellia Therapeutics by 25.3% in the second quarter. ARK Investment Management LLC now owns 4,513,584 shares of the company’s stock valued at $123,492,000 after purchasing an additional 910,608 shares during the last quarter. BlackRock Inc. increased its stake in Intellia Therapeutics by 48.4% in the second quarter. BlackRock Inc. now owns 2,556,299 shares of the company’s stock valued at $69,940,000 after purchasing an additional 833,337 shares during the last quarter. Morgan Stanley increased its stake in Intellia Therapeutics by 17.0% in the second quarter. Morgan Stanley now owns 2,234,299 shares of the company’s stock valued at $61,129,000 after purchasing an additional 324,280 shares during the last quarter. Chevy Chase Trust Holdings Inc. increased its stake in Intellia Therapeutics by 11.5% in the second quarter. Chevy Chase Trust Holdings Inc. now owns 655,882 shares of the company’s stock valued at $17,945,000 after purchasing an additional 67,714 shares during the last quarter. Finally, Federated Investors Inc. PA increased its stake in Intellia Therapeutics by 4.5% in the second quarter. Federated Investors Inc. PA now owns 625,300 shares of the company’s stock valued at $17,108,000 after purchasing an additional 27,200 shares during the last quarter. Institutional investors own 66.51% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

See Also: Investing in Dividend Stocks

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply